- JP-listed companies
- Income statement
(4890) Income statement
Market cap
¥5.6B
P/E ratio
Tsubota Lab develops innovative treatments for eye conditions like myopia, dry eye, and presbyopia, plus brain diseases, using research from Keio University.
| 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Revenue | 155 | 189 | 91 | 442 | 688 | 641 | 955 | 674 | 1,357 | 200 |
| Revenue growth (%) | - | |||||||||
| Cost of revenue | - | - | - | 165 | 81 | 84 | 236 | 652 | 180 | 68 |
| Gross profit | - | - | - | 277 | 607 | 557 | 719 | 21 | 1,177 | 132 |
| Gross margin (%) | - | - | - | |||||||
| Operating margin (%) | - | - | - | |||||||
| Operating expenses | - | - | - | 262 | 357 | 421 | 552 | 671 | 941 | 919 |
| Operating income | - | - | - | 15 | 250 | 136 | 167 | -650 | 235 | -787 |
| Income before tax | 7 | 11 | -79 | 17 | 256 | 202 | 144 | -636 | 281 | -760 |
| Pretax margin (%) | 4.8 | 5.6 | -87.1 | 3.8 | 37.2 | 31.6 | 15.1 | -94.5 | 20.7 | -380 |
| Provision for income taxes | - | - | - | 1 | 54 | 49 | 54 | 5 | 75 | 1 |
| Effective tax rate (%) | - | - | - | |||||||
| Net income | 6 | 8 | -80 | 3 | 202 | 153 | 90 | -641 | 206 | -761 |
| Earnings per share | 35.14 | 43.18 | -372.95 | 0.14 | 8.97 | 6.77 | 3.66 | -25.15 | 8.04 | -29.58 |
| Diluted EPS | - | - | - | - | - | - | 3.52 | - | 7.92 | - |
| Dividend payout ratio (%) | - | - | - | - | - | - | - | - | - | - |
| Dividend per share | - | - | - | - | - | - | - | - | - | - |